Dogwood Therapeutics, Inc., a development-stage biotechnology company, focuses on developing novel antiviral therapies to treat diseases associated with a viral triggered abnormal immune response. The company is headquartered in Alpharetta, Georgia.
| Revenue (TTM) | 0 |
| Gross Profit (TTM) | 0 |
| EBITDA | $-28.61M |
| Operating Margin | 0.00% |
| Return on Equity | -34.70% |
| Return on Assets | -18.60% |
| Revenue/Share (TTM) | $0.00 |
| Book Value | $2.41 |
| Price-to-Book | 0.62 |
| Price-to-Sales (TTM) | — |
| EV/Revenue | - |
| EV/EBITDA | 0.22 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 0.00% |
| Shares Outstanding | $33.63M |
| Float | $5.30M |
| % Insiders | 73.35% |
| % Institutions | 10.97% |
Volatility is currently expanding
Veteran Biopharma Executive and Venture Investor to Lead Newly Formed Dogwood Advisory Board in advance of Halneuron® Phase 2b Data Which is Projected for Fall of 2026 Veteran Biopharma Executive and Venture Investor to Lead Newly Formed Dogwood Advisory Board in advance of Halneuron® Phase 2b Data Which is Projected for Fall of 2026
Dogwood Therapeutics, Inc. (DWTX) Shareholder/Analyst Call Prepared Remarks Transcript
New study to assess Halneuron ® pain reduction effect over three months of treatment, additional safety data to bolster planned end of Phase 2 FDA submission package
- Halneuron ® Phase 2b trial in Chemotherapy Induced Neuropathy on track for top-line results in fall 2026 -
